Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15656249 | 0.86 | ALDH1A1 (0.77) | HTTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL15654670 | 0.82 | HTT (0.65) | HTTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL26508519 | 0.80 | HTT (0.61) | HTTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL26508546 | 0.79 | HTT (0.60) | HTTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL24265151 | 0.79 | HTT (0.60) | HTTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL5283603 | 0.78 | HTT (0.60) | HTTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL25232022 | 0.78 | HTT (0.56) | HTTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL3170230 | 0.77 | LMNA (0.64) | ALDH1A1KMT2ASMN1; SMN2KDM4EMAPK1 | |
| SCHEMBL5292301 | 0.77 | AURKA (0.48) | HTTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26924222 | 0.77 | NPC1 (0.50) | HTTALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | HTT 4781/4885ALDH1A1 2972/4885MEN1 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.